ModifiedBlue Cross Blue Shield - New MexicoPolicy CPCPLAB045

Pathogen Panel Testing

Reimbursement and coding policy for outpatient pathogen panel laboratory testing (respiratory, GI, blood, CSF, urine, wound) describing when multiplex or antigen panel testing is reimbursable or not for BCBSNM members and providers.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyPathogen Panel Testing

Policy CodePolicy CPCPLAB045

Change TypeMaterial reimbursement and exclusions updates

Effective Date01/03/2026

Next Review DateN/A

Key ActionSubmit accurate documentation and claims using valid HIPAA-approved code sets; provide additional documentation upon request.

SourceLink

POLICY UPDATE CHANGES

Revised reimbursement statements to allow multiplex PCR respiratory panels of up to 5 pathogens for individuals displaying signs/symptoms of respiratory tract infection; immunocompromised individuals may be eligible for multiplex PCR panels of up to 25 pathogens; panels of 6 or more pathogens are not reimbursable except as described.

Added several HCPCS/CPT Category I or III codes (e.g., 87428, 0556U, 0563U, 0564U; later additions include 0590U, 0593U; earlier additions include 0202U, 0223U, 0225U, 0531U; 0528U; 0441U, 0442U, 0480U, 0504U).

Reimbursement Information statements updated to specify outpatient setting and clarified language (removed leading 'In the outpatient setting..').

Explicit policy statements removing reimbursement for molecular-based panel testing for general screening of microorganisms (examples: vaginal swab panels like SmartJane™, urine panels like UroSwab®, MicroGenDX qPCR+NGS).

up to 5respiratory pathogens reimbursable (symptomatic)

up to 25

Coverage Criteria for Outpatient Pathogen Panel Testing

Outpatient pathogen panel reimbursement criteria

Covered when ALL of the following outpatient conditions are met:

ALL of the following

Policy applies only to testing performed in the outpatient setting; criteria do not apply to testing in other than the outpatient setting.
ANY of the following
- ALL of the following
  - Individual is displaying signs and symptoms of a respiratory tract infection (see Note 1).
  - Panel testing of up to 5 respiratory pathogens (antigen panel testing or multiplex PCR-based panel testing) may be reimbursable.
- ALL of the following
  - Individual is immunocompromised and is displaying signs and symptoms of a respiratory tract infection (see Note 1).
  - Multiplex PCR-based panel testing of up to 25 respiratory pathogens may be reimbursable.
ALL of the following
- For all situations not described above, antigen panel testing or multiplex PCR-based panel testing of 6 or more respiratory pathogens is not reimbursable.

ALL of the following

ANY of the following
- Multiplex PCR-based panel testing of pathogens in cerebrospinal fluid (CSF) is not reimbursable.
- Molecular detection-based panel testing of pathogens in the blood is not reimbursable.
- Molecular detection-based panel testing of urine pathogens for the diagnosis of urinary tract infections (e.g., GENETWORx Molecular PCR UTI Test) is not reimbursable.
- Molecular-based panel testing to screen for or diagnose wound infections (e.g., GENETWORx PCR Wound Testing) is not reimbursable.
- Molecular-based panel testing for general screening of microorganisms (e.g., MicroGenDX qPCR+NGS) is not reimbursable.

ALL of the following

Providers must submit claims using valid codes and supporting documentation; claims are subject to plan documents, provider contract language, medical policies, clinical payment and coding policies and code edit protocols.

Reimbursement criteria and exclusions (excerpted)

Excerpted reimbursement criteria, update history highlights, and explicit exclusions:

ALL of the following

Revised reimbursement statements to permit multiplex PCR respiratory panels of up to 5 pathogens for individuals with signs/symptoms (see Note 1) and to permit up to 25 pathogens for immunocompromised symptomatic individuals; clarified that panels of 6 or more respiratory pathogens are not reimbursable except as described; Note 1 (signs/symptoms) was added.
Policy history documents additions and removals of multiple procedure codes with listed effective dates (examples: added 87428, 0556U, 0563U, 0564U; added 0590U and 0593U effective 10/1/2025; added 0202U, 0223U, 0225U, 0531U on 04/15/2025; added 0528U effective 01/01/2025; added 0441U, 0442U, 0480U, 0504U on 10/30/2024; removed codes such as 0240U, 0151U, 0416U in various updates).

ALL of the following

Molecular-based panel testing for general screening of microorganisms (examples: vaginal swab panels such as SmartJane™, urine panels such as UroSwab®, MicroGenDX qPCR+NGS) is not reimbursable.

Procedure Codes and Reimbursement Limits

Listed procedure codesmixed

87154
87428
87483
87631
87632
87633
87636
87637
0068U
0086U

1–10 of 34

1/4

Listed added codes (history)mixed

87428	Code added per policy update history
0556U	Code added per policy update history
0563U	Code added per policy update history
0564U	Code added per policy update history
0590U	Code added effective 10/1/2025 per update history
0593U	Code added effective 10/1/2025 per update history
0202U	Code added per 04/15/2025 summary
0223U	Code added per 04/15/2025 summary
0225U	Code added per 04/15/2025 summary
0531U	Code added per 04/15/2025 summary

1–10 of 15

1/2

respiratory_panel_pathogen_count_limit

Respiratory pathogen count for symptomatic non‑immunocompromisedPanel testing of up to 5 respiratory pathogens (antigen panel or multiplex PCR) may be reimbursable for individuals displaying signs and symptoms of a respiratory tract infection.

Respiratory pathogen count for immunocompromised symptomatic individualsMultiplex PCR-based panel testing of up to 25 respiratory pathogens may be reimbursable for immunocompromised individuals displaying signs and symptoms of a respiratory tract infection.

General non‑reimbursable thresholdAntigen panel testing or multiplex PCR-based panel testing of 6 or more respiratory pathogens is not reimbursable for situations not described above.

Maximum reimbursable respiratory panel targets (symptomatic non-immunocompromised)

Maximum reimbursable targets (symptomatic, non‑immunocompromised)

Provider Responsibilities and Billing Guidance

Documentation Required

Documentation and claim review expectations

Providers are responsible for submitting accurate documentation and claims. Claims must use valid HIPAA code sets and follow industry coding guidelines (UB Editor, AMA CPT, HCPCS, ICD-10-CM/PCS, NDCs, DRG guidance, CMS NCCI policy manual and CCI edits). Claims are subject to code edit protocols and review against benefit coverage, provider contract language, medical policies, clinical payment and coding policies, and coding software logic. Upon request, providers should furnish additional documentation to support medical necessity and coding.

Submit claims using valid HIPAA code sets and industry-standard coding guidelines.
Respond to requests for additional documentation to support claims and medical necessity.
Claims are subject to code edits and policy, contract, and benefit determinations.

Note

Outpatient setting limitation

This policy applies only to testing performed in the outpatient setting. The reimbursement criteria and limitations described in the policy do not apply to inpatient, emergency, or other non-outpatient settings. Providers should use appropriate setting-specific policies and billing rules when services are rendered outside the outpatient setting.

Definitions and Notes

CPCPLAB045 Version 2.0 — policy identifier/version

Policy identifierCPCPLAB045

VersionVersion 2.0

Approval date09/26/2025

Plan effective date01/03/2026

Outpatient — definition / limitation of outpatient setting where criteria apply

Definition (outpatient scope)This policy is specific to testing in the outpatient setting; criteria below do not apply to testing in other than the outpatient setting.

Implication for claims

Document Revision History

09/26/2025policy_revision

Revised outpatient respiratory panel reimbursement: up to 5 pathogens for symptomatic individuals and up to 25 for immunocompromised symptomatic individuals; panels of 6 or more respiratory pathogens not reimbursable; added Note 1 defining signs and symptoms of respiratory tract infection; added codes 87428, 0556U, 0563U, 0564U and removed code 0240U.

08/08/2025code_addition

Added HCPCS/CPT Category III codes 0590U and 0593U, effective 10/01/2025.

01/23/2025code_addition

Added codes 0202U, 0223U, 0225U, and 0531U (listed in 04/15/2025 summary).

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyPathogen Panel Testing

Policy CodePolicy CPCPLAB045

Change TypeMaterial reimbursement and exclusions updates

Effective Date01/03/2026

Next Review DateN/A

Key ActionSubmit accurate documentation and claims using valid HIPAA-approved code sets; provide additional documentation upon request.

SourceLink

On This Page

Maximum reimbursable respiratory panel targets (symptomatic immunocompromised)

Maximum reimbursable targets (symptomatic, immunocompromised)Multiplex PCR-based panel testing of up to 25 respiratory pathogens may be reimbursable for immunocompromised individuals displaying signs and symptoms of a respiratory tract infection (see Note 1).

Test modalityAllowance explicitly applies to multiplex PCR-based panel testing (not antigen panels) for the 25‑pathogen scenario.

Outpatient limitationApplies only in the outpatient setting; criteria do not apply to other settings.

Panels not reimbursable threshold (general)

Threshold for non‑reimbursementAntigen panel testing or multiplex PCR-based panel testing of 6 or more respiratory pathogens is not reimbursable for all situations not specifically allowed.

Exceptions pathExceptions exist only as described (e.g., symptomatic individuals up to 5; immunocompromised up to 25) per policy update language.

Related specimen/site exclusionsPolicy separately identifies other non‑reimbursable specimen/site molecular panels (CSF, blood, urine, wound, general screening) which remain not reimbursable regardless of pathogen count.

Prior Authorization

Prior authorization / coding impact (history)

Prior authorization and coding outcomes have changed over time — review the policy update history for code-level and reimbursement impacts. Recent updates include additions and removals of specific CPT/HCPCS level II codes which may affect billing and reimbursement determination. Providers should verify code coverage and reimbursement implications for the member's plan and the service date.

09/26/2025 (effective 01/03/2026): Revised reimbursement criteria; added codes 87428, 0556U, 0563U, 0564U; removed 0240U.
08/08/2025: Added codes 0590U, 0593U (effective 10/01/2025).
01/23/2025: Added codes 0202U, 0223U, 0225U, 0531U.
11/19/2024: Added CPT code 0528U (effective 01/01/2025).
10/30/2024: Added codes 0441U, 0442U, 0480U, 0504U; removed codes 0151U, 0416U.

Note 1 (signs and symptoms of respiratory tract infection)

Reference for symptomatic criteriaNote 1 (signs and symptoms of respiratory tract infection) is referenced in the respiratory panel reimbursement statements to define the clinical presentation required.

Use in reimbursement determinationsPolicy language specifies 'displaying signs and symptoms of a respiratory tract infection (see Note 1)' as a prerequisite for up to 5 pathogen panels (or up to 25 for immunocompromised).

Added in updateNote 1 with signs and symptoms of respiratory tract infection was added in the 09/26/2025 update (effective 01/03/2026).

General screening molecular panels — examples (not reimbursable)

Examples of general screening molecular panels (not reimbursable)Vaginal swab panels such as SmartJane™; urine panels such as UroSwab®; MicroGenDX qPCR+NGS.

Named tests added as examplesGENETWORx Molecular PCR UTI Test and GENETWORx PCR Wound Testing are explicitly cited as examples of non‑reimbursable molecular panel tests for urine and wound respectively.

Policy stanceMolecular-based panel testing for general screening of microorganisms is not reimbursable; examples provided are illustrative, not exhaustive.